India's Commerce Ministry announced on June 8, 2026 that aquaculture products, eggs, honey and animal casings would retain EU market access under a revised antimicrobial framework. Regulation 2026/1189 lists India for those four categories; the additional import requirements began applying on September 3.
The restrictions target two uses of veterinary medicines: antimicrobials administered to promote growth or increase production, and substances reserved for treating specified infections in humans. They apply throughout the lives of the animals concerned. That makes the history of medicine use relevant to an export product, not just its condition when packed for shipment.
The country list is organised by commodity. India's entry for aquaculture therefore cannot be read as permission for every animal product. This product-by-product structure allows the EU to assess the guarantees behind particular supply chains, rather than treating an exporting country's food industry as a single category.
At EU border posts, officials check both the origin's eligibility and the health certificate's antimicrobial attestation. Risk-based controls can include identity checks, physical examination and laboratory sampling; non-compliant consignments can be rejected. For exporters, the listing and the certificate serve different purposes: one establishes the permitted country-product route, while the other accompanies the individual shipment.
On the Indian side, the ministry identified the Export Inspection Council's inspection, testing and certification work as part of the official control system. Together, these requirements link animal-rearing practices, export certification and border scrutiny. The commercial benefit is continuity of a regulated trade route for the four categories, with compliance obligations extending back into production.
